232 results
Page 2 of 12
8-K
EX-99.1
fcj7z15yw i5dlkx
29 Feb 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
8:30am
8-K
EX-99.1
0e5216r2qj3r9 3i8w2u
14 Feb 24
Other Events
8:52am
8-K
EX-99.1
xqxuyf 00kmgk4i
1 Feb 24
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
8:30am
8-K
EX-99.1
37xucqdjnt4rn9xzoo
18 Jan 24
Full Data Readout Expected in the Second Half of 2024
8:30am
8-K
EX-99.1
bd1lief30 i4ys
28 Dec 23
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
9:00am
8-K
EX-99.1
s2l1tcpdfio1
19 Dec 23
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
9:03am
8-K
EX-99.1
9q513wyvdltx
7 Dec 23
Regulation FD Disclosure
9:20am
8-K
EX-99.1
52cf6tj9xf 1b746bvp
13 Nov 23
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
bksom7ptlhlbsnjyupi
6 Nov 23
Departure of Directors or Certain Officers
8:20am
8-K
4361vjxyh9anme lgalx
30 Oct 23
Departure of Directors or Certain Officers
8:06am
8-K
EX-99.1
1emlls7
22 Sep 23
Regulation FD Disclosure
8:03am
8-K
EX-99.1
7cwfxq806 3uk32onm
15 Sep 23
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
8:11am
8-K
EX-99.1
wg53wau
14 Aug 23
Neurobo Pharmaceuticals Appoints Hyung Heon Kim
8:18am
8-K
ogt nqr2zg
14 Aug 23
Neurobo Pharmaceuticals Appoints Hyung Heon Kim
8:18am
8-K
EX-10.1
52u cvn5c4tw
14 Aug 23
Neurobo Pharmaceuticals Appoints Hyung Heon Kim
8:18am
8-K
EX-99.1
s0vwf6i2g56 0kq
9 Aug 23
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:20pm
8-K
EX-99.1
549wubeq3f5
3 Aug 23
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its
8:15am
8-K
EX-99.1
ck71uewz62
27 Jun 23
Other Events
8:26am